c-RET
c-RET inhibitors target the RET (Rearranged during Transfection) proto-oncogene, which encodes a receptor tyrosine kinase involved in cell growth, differentiation, and survival. Abnormal activation of RET signaling can lead to uncontrolled cell proliferation and resistance to apoptosis, contributing to the development of cancers such as medullary thyroid carcinoma and non-small cell lung cancer. Inhibiting c-RET can induce apoptosis in cancer cells and is a promising approach in targeted cancer therapy. At CymitQuimica, we offer a variety of high-quality c-RET inhibitors to support your research in oncology, signal transduction, and apoptosis.
Found 61 products of "c-RET"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Formula:C23H27F4N3O4SPurity:99.23%Color and Shape:SolidMolecular weight:517.54Ref: TM-T10624
1mg43.00€2mg57.00€5mg96.00€10mg134.00€25mg220.00€50mg329.00€100mg470.00€1mL*10mM (DMSO)97.00€RET-IN-4
CAS:RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Formula:C27H31FN10O2Color and Shape:SolidMolecular weight:546.611RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Formula:C38H42N10O3Color and Shape:SolidMolecular weight:686.81YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Formula:C58H63F3N12O9Color and Shape:SolidMolecular weight:1129.19AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Formula:C22H21ClF3N7OPurity:98%Color and Shape:SolidMolecular weight:491.9RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Color and Shape:Odour SolidCDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Formula:C29H26N4OMolecular weight:446.21066Cofetuzumab
CAS:Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.Purity:>95%Color and Shape:LiquidRET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Formula:C22H22N6OColor and Shape:SolidMolecular weight:386.45PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formula:C22H22FN5O2Color and Shape:SolidMolecular weight:407.44RET-IN-28
CAS:RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Formula:C26H29N9Color and Shape:SolidMolecular weight:467.57Zeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Formula:C56H56F6N8O12Color and Shape:SolidMolecular weight:1147.098BT44
CAS:BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Formula:C28H27F4N3O4SPurity:99.87%Color and Shape:SoildMolecular weight:577.59Ref: TM-T67733
1mg74.00€5mg160.00€10mg235.00€25mg424.00€50mg635.00€100mg924.00€1mL*10mM (DMSO)188.00€QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Formula:C53H54N12O4Color and Shape:SolidMolecular weight:923.07Compound TPX-0046
CAS:Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Formula:C21H21FN6O3Purity:99.94%Color and Shape:SoildMolecular weight:424.43RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Formula:C40H44N10OColor and Shape:SolidMolecular weight:680.84RET ligand-1
CAS:RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Formula:C28H24F2N6O3Color and Shape:SolidMolecular weight:530.525trans-Pralsetinib
CAS:trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).Formula:C27H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:533.6Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFormula:C27H32FN9O2Purity:97.88% - 99.8%Color and Shape:SolidMolecular weight:533.6Ref: TM-TQ0277
1mg43.00€5mg103.00€10mg145.00€25mg283.00€50mg439.00€100mg660.00€1mL*10mM (DMSO)120.00€WHI-P180
CAS:WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Formula:C16H15N3O3Purity:99.21%Color and Shape:SolidMolecular weight:297.31BBT594
CAS:BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.Formula:C28H30F3N7O3Purity:99.57%Color and Shape:SolidMolecular weight:569.58RET V804M-IN-1
CAS:RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).Formula:C19H16N6OPurity:97.94% - 99.62%Color and Shape:SolidMolecular weight:344.37Ref: TM-T8467
1mg35.00€2mg50.00€5mg74.00€10mg90.00€25mg157.00€50mg236.00€100mg334.00€200mg495.00€1mL*10mM (DMSO)82.00€TPX-0046
CAS:TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
Formula:C21H21FN6O3Purity:99.95%Color and Shape:SolidMolecular weight:424.43Selpercatinib
CAS:"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Formula:C29H31N7O3Purity:99.89% - >99.99%Color and Shape:SolidMolecular weight:525.6Ref: TM-T8222
2mg35.00€5mg51.00€10mg88.00€25mg170.00€50mg274.00€100mg505.00€200mg730.00€500mg1,093.00€1mL*10mM (DMSO)59.00€Pyrazoloadenine
CAS:Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Formula:C5H5N5Purity:99.02%Color and Shape:Beige PowderMolecular weight:135.13GSK3179106
CAS:GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nMFormula:C22H21F4N3O4Purity:99.8% - 99.90%Color and Shape:SolidMolecular weight:467.41Treprostinil Sodium
CAS:Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).Formula:C23H33NaO5Purity:99.67% - >99.99%Color and Shape:SolidMolecular weight:412.5SPP-86
CAS:SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Formula:C16H15N5Purity:99.53%Color and Shape:SolidMolecular weight:277.32Ref: TM-T16923
1mg46.00€5mg90.00€10mg144.00€25mg281.00€50mg447.00€100mg650.00€500mg1,369.00€1mL*10mM (DMSO)90.00€WHI-P180 hydrochloride
CAS:WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Formula:C16H16ClN3O3Color and Shape:SolidMolecular weight:333.77AD80
CAS:AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.Formula:C22H19F4N7OPurity:99.49% - 99.75%Color and Shape:SolidMolecular weight:473.43Ref: TM-T4301
1mg47.00€5mg92.00€10mg145.00€25mg283.00€50mg464.00€100mg680.00€500mg1,406.00€1mL*10mM (DMSO)96.00€RET-IN-16
CAS:RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.Formula:C31H29F3N8O2Color and Shape:SolidMolecular weight:602.61RET-IN-15
CAS:RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Formula:C27H28N8O2Color and Shape:SolidMolecular weight:496.56RET-IN-8
CAS:RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Formula:C27H30N6O3Color and Shape:SolidMolecular weight:486.57RET-IN-12
CAS:RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).Formula:C30H30F3N5O4Color and Shape:SolidMolecular weight:581.59RET-IN-6
CAS:RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).Formula:C30H29N7Color and Shape:SolidMolecular weight:487.6RET-IN-22
CAS:RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-Formula:C29H31F3N6O4Color and Shape:SolidMolecular weight:584.59XMD15-44
CAS:XMD15-44, a RET kinase inhibitor, demonstrates potent growth-inhibitory effects on RAT1 cells transformed by RET/C634R and RET/M918T, with IC50 values of 11.5 nM and 8.3 nM, respectively. It effectively inhibits RET kinase activity and signaling in human thyroid cancer cell lines harboring oncogenic RET alleles, thereby reducing cell proliferation.Formula:C29H29F3N4OColor and Shape:SolidMolecular weight:506.56DUN73423
CAS:DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.Formula:C19H16N6OPurity:98.09%Color and Shape:SolidMolecular weight:344.37TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Formula:C29H31F3N8OPurity:98%Color and Shape:SolidMolecular weight:564.6RET-IN-3
CAS:RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.Formula:C18H21N5O2Purity:99.52%Color and Shape:SolidMolecular weight:339.39Ref: TM-T9673
1mg73.00€5mg158.00€10mg240.00€25mg452.00€50mg712.00€100mg1,093.00€200mg1,473.00€1mL*10mM (DMSO)168.00€RET-IN-23
CAS:RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.Formula:C28H28FN11Purity:97.46%Color and Shape:SolidMolecular weight:537.59TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFormula:C26H34N6O3SPurity:98.68%Color and Shape:SolidMolecular weight:510.65Pz-1
CAS:Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Formula:C26H26N6O2Purity:99.89%Color and Shape:SolidMolecular weight:454.52RET-IN-13
CAS:RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.Formula:C32H33F4N5O3Color and Shape:SolidMolecular weight:611.63NSC194598
CAS:NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Formula:C20H19N3OColor and Shape:SolidMolecular weight:317.38FHND5071
CAS:FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFormula:C30H30D3N9OColor and Shape:SolidMolecular weight:538.66FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Formula:C25H22N4O5Color and Shape:SolidMolecular weight:458.47RET-IN-5
CAS:RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).Formula:C29H26FN9OColor and Shape:SolidMolecular weight:535.57RET-IN-24
CAS:RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Formula:C27H26F2N8OColor and Shape:SolidMolecular weight:516.55RET-IN-25
CAS:RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFormula:C22H17N3O5SColor and Shape:SolidMolecular weight:435.45RET-IN-17
CAS:RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Formula:C27H28F4N4O4Color and Shape:SolidMolecular weight:548.53RET-IN-9
CAS:RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.Formula:C26H27N9OColor and Shape:SolidMolecular weight:481.55LRRK2-IN-17
CAS:LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).Formula:C18H18N8Color and Shape:SolidMolecular weight:346.39FHND5071 (1H)
CAS:FHND5071 (1H) is a selective inhibitor of RET (rearranged during transfection) tyrosine kinase. It shows potential for research applications in RET-driven cancers, such as thyroid and lung cancer.Formula:C30H33N9OColor and Shape:SolidMolecular weight:535.64TAS05567
CAS:TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Formula:C21H29N9O2Purity:98%Color and Shape:SolidMolecular weight:439.51RET-IN-30
CAS:RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. It is capable of inhibiting the proliferation of A549 cells and demonstrates antitumor properties.Formula:C26H26FN5OColor and Shape:SolidMolecular weight:443.52RET-IN-10
CAS:RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).Formula:C29H28N8OSColor and Shape:SolidMolecular weight:536.65RET-IN-7
CAS:RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice throughFormula:C22H24ClFN6O2Color and Shape:SolidMolecular weight:458.92RET-IN-1
CAS:RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).Formula:C29H31N9O3Purity:98%Color and Shape:SolidMolecular weight:553.61WF-47-JS03
WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.
Formula:C30H38N6O2Color and Shape:SolidMolecular weight:514.66Enbezotinib
CAS:Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Formula:C21H21FN6O3Purity:99.84%Color and Shape:SolidMolecular weight:424.43Ref: TM-T62285
1mg77.00€5mg166.00€10mg253.00€25mg414.00€50mg567.00€100mg745.00€1mL*10mM (DMSO)182.00€
